Meclocycline Sulfosalicylate

Summary

Meclocycline Sulfosalicylate (CHEMBL261772) is an approved small molecule; indicated across 2 conditions including stomatitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Chemistry: 695 Da · C29H27ClN2O14S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL261772
Name	Meclocycline Sulfosalicylate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54676538
Molecular formula	C29H27ClN2O14S
Molecular weight	695
InChIKey	WVJKUGVVYXCLFV-CCHMMTNSSA-N

SMILES: CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O.C1=CC(=C(C=C1S(=O)(=O)O)C(=O)O)O

IUPAC name: (4S,4aR,5S,5aR,12aR)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;2-hydroxy-5-sulfobenzoic acid

Also known as: Meclan, Meclocycline sulfosalicylate, Meclocyline sulfosalicylate, Meclocil, Mecloderm, Meclosorb, NSC-757831, Quoderm, SNX-1012, Traumatociclina, meclocycline sulfosalicylate, SID56463024

Patent coverage: 268 distinct patent families (826 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 755 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Lethal(3)malignant brain tumor-like protein 1, Ubiquitin carboxyl-terminal hydrolase 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
L3MBTL1	6.35	Potency	446.7	nM	CHEMBL_ACT_4617165

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
stomatitis	2	MONDO:0004842	EFO:1001904

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).